Physician profile
Sandra Gadson
NPI 1841297348
$3,128.66
in general payments reported to CMS, 2019-2025
27 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $200 · 2021: $262 · 2022: $691 · 2023: $670 · 2024: $447 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.60 | 2019-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $421.60 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $360.26 | 2019-2024 | Rayaldee |
| Vifor Pharma, INC. | $260.01 | 2019-2023 | Veltassa |
| Amgen INC. | $177.93 | 2019-2025 | Krystexxa, Tavneos |
| Cook Medical LLC | $127.76 | 2023 | Cook |
| Ani Pharmaceuticals, INC. | $114.78 | 2022-2025 | Purified Cortrophin Gel |
| Acell, INC. | $108.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $101.81 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $100.78 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $95.48 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $90.89 | 2023-2024 | |
| Glaxosmithkline, LLC. | $90.41 | 2021-2023 | Benlysta |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.30 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.59 | 2023-2025 | Ozempic |
| Lilly USA, LLC | $65.39 | 2024-2025 | Jardiance |
| Nxstage Medical, INC. | $58.59 | 2019 | |
| Daiichi Sankyo INC. | $48.23 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $45.00 | 2024 | |
| Scpharmaceuticals INC. | $32.94 | 2025 | |
| Novartis Pharmaceuticals Corporation | $28.25 | 2019-2024 | |
| Ultragenyx Pharmaceutical INC. | $22.98 | 2020 | |
| Kyowa Kirin, INC. | $19.82 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.75 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $16.45 | 2019 | |
| Aurinia Pharma U.S., INC. | $14.62 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Gadson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.